On November 22, 2024, Clay Siegall, President and Chief Executive Officer of Immunome Inc (IMNM, Financial), acquired 100,000 shares of the company, as reported in a recent SEC Filing. This transaction brings the insider's total ownership to 519,636 shares.
Immunome Inc is a biotechnology company focused on developing antibody therapeutics for cancer and infectious diseases. The company's approach leverages its proprietary discovery engine to identify novel targets and generate antibodies with unique mechanisms of action.
The recent purchase by Clay Siegall is part of a broader trend of insider activity within the company. Over the past year, the insider has purchased a total of 200,000 shares and has not sold any shares. The overall insider transaction history for Immunome Inc shows six insider buys and two insider sells over the same period.
Shares of Immunome Inc were trading at $9.62 each on the day of the insider's recent acquisition, resulting in a market cap of $672.229 million for the company.
This insider buying activity may be of interest to investors who track insider transactions as a potential indicator of a company's future performance. For more detailed valuation metrics, investors can refer to the company's GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
